Delia Jervier, executive director of the Alzheimer’s Association, joins Lisa Dent on Chicago’s Afternoon News to discuss how the new drug lecanemab developed by Biogen slowed cognitive decline in Alzheimer’s patients in clinical trials, and what it means for future treatment of the disease.

Follow Your Favorite Chicago’s Afternoon News Personalities on Twitter: